Parkinsonism & Related Disorders

Article	Citations
Objective sleep enhancement in Parkinson's disease: A sham-controlled trial of low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex	96
Cerebello-thalamofrontal dysconnectivity in paroxysmal kinesigenic dyskinesia: A resting-state fMRI study	93
Perry disease in an Argentine family due to the DCTN1 p.G67D variant	57
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?	55
Is rapid eye movement sleep behavior disorder a marker of Parkinson's disease severity?	54
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study	48
Magnetic resonance spectroscopy reveals evidence of brain oxidative stress in Tourette syndrome	46
Fear among patients with Parkinson's disease and repeated falls: Analysis of skin conductance responses during simulated accidents	46
A useful cognitive motor dual task paradigm in prodromal and manifest Huntington’s disease	44
Diet quality and prodromal Parkinson's disease probability in isolated REM sleep behavior disorder	43
Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia	43
Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: analysis of baseline factors	43
Critical Appraisal of Economic Evaluation of Biomarkers Used for Screening of Dementia	42
A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson’s Disease	41
Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS	39
White matter connectivity networks predict early dementia conversion in Parkinson’s disease	38
Association of Baseline Serum Urate Levels with Longitudinal General Cognition in Non-Demented Parkinson's Disease	37
Examination of cognitive function in Parkinson's disease patients with chronic kidney disease	37
Chorea-Acanthocytosis: A Case Report	36
Association and Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson’s Disease–related Cognitive Impairment	35
“Pop-up” studies: Observational studies in Huntington disease conducted at annual family convention	35
Targeting sedentary behavior decreases depressive symptoms and improves sleep in people with Parkinson’s Disease	34
Role of linagliptin, a dipeptidyl peptidase-4 inhibitor against oxidative stress and neuronal damage in experimental diabetic aging brain of female rats of different age groups.	34
β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome	32
Fibrinogen exacerbates GCase ubiquitination via ATF5-induced TRIP12 activation in Parkinson's Disease	32

Association between serum lipid levels and dopamine loss in idiopathic rapid eye movement sleep behavior disorder	31
Bilateral Hemimasticatory spasm in a patient with hypereosinophilic syndrome	30
Treatment of refractory post-hypoxic myoclonus and focal epilepsy with subthalamic nuclei deep brain stimulation	29
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis	28
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	28
Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyse	28
Diagnosis of vascular parkinsonism: A new tool for gait hypokinesia occurring in older persons	27
Relation between Clinical and Electrophysiological Correlates of Peripheral Polyneuropathy and Oral Levodopa Treatment in People with Parkinson’s Disease	27
Integrity of Dopaminergic Terminals in the Caudate Nucleus Modulates Rest Tremor in Parkinson’s Disease	26
Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein	25
Digital devices and wearable technology for quantification of freezing of gait in adolescents with pediatric movement disorders attending school	25
Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease	25
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration	24
Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021	24
Mitochondrial and autophagic dysfunctions of skin fibroblasts derived from pantothenate kinase-associated neurodegeneration patients carrying PANK2 mutations and the rescuing effects of allantoin	24
A case of probable Progressive Supranuclear Palsy Frontal type (PSP-F) presenting as psychosis	23
Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients With Parkinson’s Disease	23
Effects of an intensive, multidisciplinary rehabilitative treatment in an outpatient setting on clinical outcomes in Parkinson’s Disease: preliminary results.	23
APOE carrier status and cognitive outcomes after STN-DBS surgery for Parkinson’s disease.	23
Leveraging Telehealth and Wearables for Parkinson’s Disease: Innovative Approaches to Enhance Personalized Care	23
Dual Phase 18F-FP-CIT PET in presynaptic and trans-synaptic nigrostriatal dysfunction in Multiple System Atrophy	23
Malignant Neuroleptic Syndrome in a Patient with Huntington's Disease	23
Error-based biofeedback for gait training in Parkinson's disease	23
Evaluation of mild cognitive impairment in older patients with essential tremor	22
Neurocognition, Cerebellar Functions and Psychiatric Features in Spinocerebellar Ataxia Type 34	22
FindPD.DaT: Development of a Novel Artificial Intelligence-driven Tool for Diagnosis of Parkinson’s Disease using Dopamine Transporter Scans	22
Perioperative quantification of MDS-UPDRS-III tremor measurements in patients with Parkinson’s Disease using accelerometry	22
The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review	21
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	21
Longitudinal brain changes in Parkinson's disease with severe olfactory deficit	21
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	21
In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study	21
Unveiling the Complexity of Parkinson's Disease: Exploring Subtypes and Tracing its Five-Stage Natural Course	20
Functional movement disorders in dopa-responsive dystonia	20
Machine Learning Analysis of the Interaction Between miR-155 and LRRK2 Gene Variants in Parkinson's Disease Progression	20
Clinical Evaluation of Parkinson's Disease Patients Admitted to the Movement Disorders Outpatient Clinic of Istanbul Taksim Training and Research Hospital, Turkey, 2023	20
The Elevated Risk of Dementia in Parkinson's Disease Patients Associated with Metabolic Syndrome	20
Gerstmann-Straussler-Scheinker disease: Lessons from two new Indian kindreds	20
Huntington Disease – Update on Recent Advances and a Look Toward the Future	20
Retinal microvascular impairment in Parkinson's disease with cognitive dysfunction	20
From writer's cramp to blepharoclonus: An atypical journey with a novel KMT2B variant	20
The role of neurotrophic factors in development Parkinson's disease dementia	19
Somnolence-Related Events Over Time During Valbenazine Treatment for Chorea Associated with Huntington’s Disease	19
Study of 17β estradiol with neuropeptide and amyloid beta fragment on neuronal and biochemical functions in naturally menopausal aging rats	19
Establishing exercise habits in patients with Parkinson's disease through an exercise group model	19
Parkinson’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?	19
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	19
The characteristic and prognostic role of blood inflammatory markers in patients with Huntington's disease from China	18
Hereditary Spastic Paraparesis with SPG6 mutation: First case report from Malaysia	18
Efficacy of Once-Daily Valbenazine in Adults with Chorea Associated with Huntington’s Disease: Effect Size Over Time	18

Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism	18
Dentate calcifications with palatal tremor and facial myorhythmia in adult-onset Cerebral X-linked Adrenoleukodystrophy	18
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease	17
Sex differences for cognitive decline in progressive supranuclear palsy	17
Proteomic profile of saliva in patients with Parkinson's disease after the practice of interval exercise	17
Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial	17
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	17
Differences in progressive supranuclear palsy in patients of Asian ancestry?	17
The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study	17
Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy	17
Genetic study of early-onset Parkinson's disease in the Malaysian population	17
Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients	17
The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease	16
Editorial Board	16
On demand inhaled levodopa in Parkinson´s disease (pd) patients with device assisted therapies	16
Cystatin C as a Biomarker for the Development of Parkinson disease in Patients with Chronic Kidney Disease	16
Machine Learning-based World Health Organization Disability Assessment Schedule for persons with Parkinson's disease	16
Personality assessment with Temperament and Character Inventory in Parkinson's disease	16
Colony-Stimulating Factor-1 Receptor-Related Disorders in the Hispanic Population: A Report of six Families	16
A late-onset neurological disorder: Is progression inevitable? Expert Commentary	16
Tardive dyskinesia versus tardive syndrome. What is in a name?	16
Effect of Safinamide on Non-motor symptoms and QoL According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose	16
A young man with progressive dysarthria, generalized slowness and memory loss	15
Distractibility predicts favourable response of functional tremor to transcranial magnetic stimulation: An electrophysiological study	15
Frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis	15
Editorial Board	15
Dopaminergic dysfunctions instigated by Nano-formulation of Neonicotinoid pesticides in mice	15
Levodopa, homocysteine and Parkinson's disease: What's the problem?	15
Motor and non-motor responses of STN DBS in early onset PLA2G6 related Parkinsonism with compound heterozygous mutation from China	15
Atypical antipsychotic use and mortality risk in Parkinson disease	15
Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease	15
Protective Lifestyle Risk Factors Against Parkinson’s Disease In Sub-Saharan Africa: A Review On Current Evidence	15
Commentary on “The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials”	15
The psychological correlates of fatigue in Parkinson's disease: Contribution of maladaptive metacognitive beliefs	15
Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy	15
The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different cognitive status	14
A de novo GRIA3 variant with complex hyperkinetic movement disorder in a girl with developmental delay and self-limited epilepsy	14
Editorial Board	14
Efficacy and safety of high doses of safinamide in advanced Parkinson disease	14
Brittle dyskinesias after bilateral STN DBS: dissociation of microlesioning effect on tremor versus on dyskinesias	14
Segmental dystonia as the prominent phenotype resulting from a MICU1 splice variant in a new Indian case	14
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks	14
Augmented reality cueing for freezing of gait: Reviewing an emerging therapy	14
¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment In Parkinson Disease?	14
Editorial Board	14
Association of bilateral oophorectomy with incidence of Parkinson's disease: A systematic review and meta-analysis	14
Single-dose intranasal administration of α-syn PFFs induce lewy neurite-like pathology in olfactory bulbs	13
Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes	13
Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease	13
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis	13
Neuropsychological studies in children with tic hyperkinesis	13
ERCC4 variants causing neurodegeneration with ataxia and chorea in three siblings in Lithuanian family	13
Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson's disease	13
Transcranial high-intensity Magnetic Resonance-guided focused ultrasound (tcMRgFUS) – safety and impacts on tremor severity and quality of life	13
Expanding the phenotypic and genotypic spectrum of DYT-TUBB4A with seven patients from India	13
Phenotypic manifestations of KIF5A Arg1007Lys mutation: A large kindred study	13
Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline	13
Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) Presenting With Parkinsonism Findings: A Case Report	13
Introducing Virtual Shared Medical Appointments as a Novel Treatment Platform for Functional Movement Disorders	13
Convergence insufficiency and Parkinson's disease progression	13
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	13
MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease	13
Ethnoracial differences for caregiving burden in Parkinson’s disease	13
Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum	13
The factors for choosing intesticular gel therapy	13
REM density in Parkinson’s disease: Effects of motor, cognitive, and autonomic function, and the impact of evening dopaminergic medication	13
MRgFUS of the nucleus ventralis intermedius in essential tremor modulates functional connectivity within the classical tremor network and beyond	13
Real-world effect of age on long-term effectiveness and safety of levodopa-carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study	12
Grey matter correlates of dystonic soft signs in essential tremor	12
Analysis of GIPC1 CGG repeat expansions in essential tremor	12
Seronegative basal ganglia encephalitis mimicking dementia of Lewy body	12
Disparities in diagnosis, treatment and survival between Black and White Parkinson patients	12
The role of semispinalis capitis muscles in cervical dystonia with goose-neck posture	12
Tremor is associated with familial clustering of dystonia	12
The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials	12
Improvement of non-motor symptoms with NE3107 adjunctive to Carbidopa / Levodopa in patients with Parkinson`s disease: A Phase 2A, placebo-controlled study	12
Cerebellar blood perfusion is a diagnostic, but not a prognostic, marker for parkinsonian-dominant type multiple system atrophy	12
Post-COVID parkinsonism: A scoping review	12
Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders	12
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	12

Recent advances in non-Huntington's disease choreas	12
“A man with an arched back”: Expert commentary	12
C19orf12 mutation carriers and their first-degree relatives require prospective clinical and genetic work-up	12
Interaction between caffeine intake and polymorphisms of PARK16 modifies Parkinson’s Disease risk	12
Spinocerebellar ataxia subtype 40: Report of a case and review of literature	12
Late-onset parkinsonism in a patient with a novel frameshift THAP1 variant	12
Beta power and movement-related beta modulation as hallmarks of energy for plasticity induction: Implications for Parkinson's disease	12
Thyroid disease in cervical dystonia	12
Identification of the needs of patients with Parkinson’s disease through a qualitative research process	12
Differential expression of gut miRNAs in idiopathic Parkinson's disease	12
Sweet as Parkinson's disease: Rethinking the impact of diabetes mellitus	12
Sexual dysfunction in patients with focal dystonia	12
Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial	11
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study	11
Challenges during prayer (namaz/salah) rituals in Muslim patients with Parkinson’s disease	11
Usage of modern technologies like VR therapy, physio therapy along with levodopa in Young-Onset Parkinson's disease patients	11
The use of botulinum toxin A in the treatment of hand tremor	11
Reliability of remote video ratings of the scale for assessment and rating of ataxia	11
The feasibility of using loss of “swallow tail sign” on 3T – susceptibility weighted MRI in diagnosis of Parkinson’s disease	11
Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions	11
Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease	11
WITHDRAWN	11
A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene – A case series	11
Profile of patients with advanced Parkinson’s disease treated with Levodopa–entacapone–carbidopa intestinal gel (LECIG)	11
Right to the Point - A Writer’s Cramp Successful Treatment	11
Magnetic Resonance Imaging Marker for the Conversion from Idiopathic Late-onset Cerebellar Ataxia to Multiple System Atrophy	11
Patients with progressive supranuclear palsy need to be seen sooner and more frequently	11
A case of treatable encephalopathy, developmental regression, and proximal tremor: Expert commentary	11
The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study	11
Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study	11
TorsinA-interacting protein 2 (TOR1AIP2) variants in an autosomal dominant combined dystonia-hemichorea-hemiballismus syndrome in two families	11
A structural perspective on the interaction between glucocerebrosidase and the positive allosteric modulator BIA 28-6156	11
Calcium channel blockers and Parkinson's disease: A systematic review and meta-analysis	11
An atypical case of head tremor	11
Cropland associated with risk of Parkinson's disease in the northern Great Plains	11
Empowering the management of early-onset Parkinson’s disease: The role of technology	11
Longitudinal evaluation of patients with isolated head tremor	11
Motor band sign in a Huntington disease phenocopy	11
Structural and functional brain abnormalities in idiopathic cervical dystonia: a multimodal meta-analysis	10
Exposure factors and clinical characteristics associated with Parkinson's disease in GBA1 variant carriers: A Chinese GBA1-PD intrafamilial survey	10
Diagnosis across a cohort of “atypical” atypical and complex parkinsonism	10
Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson disease	10
Inter-muscular coherence in speed skaters with skater's cramp	10
Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson’s disease	10
Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study	10
Development of a screening AI model for Parkinson's disease using gait image sequences	10
A challenging case of cerebellar ataxia associated with oro facial dominant chorea	10
Accelerometric quantification of MDS-UPDRS bradykinesia measurements in PD patients: A pilot study	10
Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems	10
Impact of deep brain stimulation on quality of life and motor symptoms in Parkinson's disease and X-linked dystonia parkinsonism: The Philippine experience	10
Diagnosis of Parkinson's disease from hand drawing utilizing hybrid models	10
A case of treatable encephalopathy, developmental regression, and proximal tremor	10
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy	10
Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism	10
Editorial Board	10
Multiple system atrophy like presentation with hot-cross bun sign in anti-IgLON5 disease	10
Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study	10
Prediction of the effect of deep brain stimulation on gait freezing of Parkinson's disease	10
A relatively common hypomorphic variant in WARS2 causes monogenic disease	10
High preoperative gait variability is a prognostic predictor of gait and balance in Parkinson disease patients with deep brain stimulation	10
A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis	10
Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic?	10
An immersive virtual reality shopping task detects declines in instrumental activities of daily living in individuals with Parkinson's disease	9
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease	9
Coexistence of deep brain stimulators and cardiac implantable electronic devices: A systematic review of safety	9
Parkinson's disease patients with absence of normal dipping status were more vulnerable to cognitive impairment from the early stages	9
A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation	9
The iNPH Radscale May Better Predict Whether Ventriculoperitonal Shunting was Offered, Compared to Drain Trial Gait Variables	9
Demonstration of a Prototype Clinical Decision Support System for Diagnosing Parkinson’s Disease	9
Analysis of interleukin-6 levels in patients with Parkinson's disease by disease stage	9
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients	9
Real-world local field potential recordings in patients with deep brain stimulation for Parkinson's disease	9
Structural and functional connectomics of the olfactory system in Parkinson's disease: a systematic review	9
Double blind, nonrandomized crossover study of active recharge biphasic deep brain stimulation for primary dystonia	9
A multidisciplinary telemedicine approach for managing frailty in Parkinson's disease. A longitudinal, case-control study	9
Enhanced low beta activity in Park2-associated Parkinson’s disease	9
Evolving resting head tremor in parkinsonism: Clinicopathological study of a case	9
The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel	9
Symptom changes with hormonal variations in genetic dystonia	9
TMS-evoked potentials provide novel neurophysiological features of Tourette syndrome	9
Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease	9
Non-pharmacological rehabilitation for people living with advanced Parkinson's disease: A scoping review of interventions	9
Update: Protective and risk factors for Parkinson disease	9
Monocyte to high-density lipoprotein cholesterol ratio reflects the peripheral inflammatory state in parkinsonian disorders	9
Nigrostriatal dysfunction in RFC1-related disorder/CANVAS	9
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohort	9
Association of subthalamic beta frequency sub-bands to symptom severity in patients with Parkinson's disease: A systematic review	9
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease	9
tDCS application for postural control in Parkinson's disease: Effects are associated with baseline characteristics	9
A Novel Missense Mutation in the Spectrin Repeat of SPTBN2 Identified in Spinocerebellar Ataxia Type 5	9
Are we ready for automated deep brain stimulation programming?	9
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies	9
Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy	9
Backward leaning during gait: An underrecognized sign in Niemann-Pick type C	9
ΔHR/ΔWR derived from CPET; A novel predictor of ‘off’ symptom in Parkinson's disease	8